Home

A Shallow Dive From The Deep South

In what is shaping up as a never-ending quest to provide newsletter coverage from anyplace not named "home", this week's letter comes from Raleigh,...

Cryoport Announces Pricing of Public Offering of Common Stock

IRVINE, Calif., June 19, 2019 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) (Nasdaq: CYRXW) ("Cryoport" or the "Company") today announced the pricing of its underwritten public...

Hancock Jaffe Hires Brian Roselauf as Director of Research and Development

Tailwinds' Take: HJLI is positioning for a pivotal trial; something that is definitely not priced into the stock at its current level. The disconnect...

Hancock Jaffe Primary Investigator Dr. Jorge Hernando Ulloa to Present VenoValve Report at the...

Tailwinds' Take: the success shown to date in the ongoing first-in-human trials of the VenoValve is starting to garner significant recognition. Presenting data at...

Daxor Corporation Announces New Research Initiative with Leading Hospital in the Southeast and the...

NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume...

The Trade War Observer; OS Splitting

Technology has become the main battleground in the Sino-US rivalry. The trade war must be viewed in that context. This is why, despite of the US’s...

Hancock Jaffe CEO Interview

On June 7, 2019, Hancock Jaffe Laboratories, Inc.  (Nasdaq: “HJLI”) released the first data from its VenoValve first-in-human trial that is underway in Bogota,...

Hancock Jaffe Successfully Completes VenoValve Implantation for First-in-Human Study

IRVINE, California, June 13, 2019 – Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a developer of medical devices that restore cardiac and vascular health,...

WiSA Announces Certification of the SC15 and PRE35 From Primare’s Prisma Line

Tailwinds' Take: "widespread adoption" happening is music to our ears. WISA represents an opportunity to pick up a developer of a unique platform technology...

BioVie’s FDA Meeting Approaching Rapidly

After releasing positive top-line results from their Phase 2a trial in late April, BioVie (BIVI) has been rather quiet. This is to be expected...

Hancock Jaffe Announces Pricing of Public Offering of Common Stock

Tailwinds' Take: excited to see balance sheet risk off the table for a while here, although the terms of this financing were very steep...

Three Thoughts on Anixa’s S-3

This afternoon Anixa (ANIX) filed a mixed-shelf offering of up to $100M in securities. Included in this was a sales agreement with B. Riley...

PeerStream, Self-Funding a Secure Messaging Platform

I consider the typical Tailwinds stock to be "public venture capital". These are public companies that have all the characteristics of private, venture companies....

Hancock Jaffe Reports Early Positive Results from First-In-Human VenoValve Study

Tailwinds' Take: excellent results that bode well for a positive path towards approval. The VenoValve could be a multi-billion dollar product within several years....

Catasys Adds Canary Health to OnTrak Platform

Los Angeles, CA – June 6, 2019 – Catasys, Inc. (NASDAQ: CATS) ("Catasys" or the "Company"), a leading AI and technology-enabled healthcare company, today...

HyreCar Is Revving Up

With the recent IPOs of UBER and LYFT, Mobility-as-a-Service (MAAS) is an industry that is drawing major investor attention. Unfortunately, that attention hasn't been...

Hancock Jaffe Enrolls Two Additional Patients for First-in-Human VenoValve Study

Tailwinds' Take: HJLI is executing to their game plan. The VenoValve is on schedule and we expect to see positive data from early patients...

Markets Trade Down In May…June Preview

I'm not sure why, but it seems that every time I feel the Tailwinds' Portfolio is poised for big gains, the market enters a...

Bioasis Appoints Mario Saltarelli as Non-Executive Director of the Board of Directors

GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (OTCQB:BIOAF; TSX.V:BTI), ), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 TM platform technology for the delivery of therapeutics across the...

A Brief Update on Anixa

Yesterday I had the opportunity to sit down with Anixa’s Dr. Amit Kumar, CEO, and Michael Catelani, CFO. Our discussion was rather wide ranging...

Become a Tailwinds member

Due to Tailwinds’ status as a Registered Investment Advisor, we are required to monitor our usage. Therefore you must be a Tailwinds Research member to read our articles. All articles are free for viewing, except for Premium Membership articles related to changes in the Tailwinds Select Portfolio.

Please take the time to register for a Free or Premium membership. Thank you for your support.

SIGN ME UP